Vietnamese Journal of Neurology

Article detail

Article detail description

Home
Articles Issue: Vietnamese Journal of Neurology No.40 Ca lâm sàng

Diagnosis and treatment challengesin Multiple Sclerosis with very-Late onset: A case report

Published: April 11, 2024
Views: 3

Abstract

Multiple sclerosis is a prevalent chronic inflammatory demyelinating disease of the central nervous system that affects mainly young adults. Patients with onset after the age of 50 years are defined as late-onset MS (LOMS), and the others with onset after 60 years are termed very late-onset MS (VLOMS). Due to the rarity, and variations in clinical presentation, coupled with the lack of clinical trials for disease-modifying therapies (DMTs), diagnosis and treatment are challenging in these groups. In our clinical case, we describe a patient diagnosed with VLOMS at the Neurology Department of Military Hospital 175.

References

1.
Naseri, A., et al., Clinical Features of Late-Onset Multiple Sclerosis: a Systematic Review and Meta-analysis. Mult Scler Relat Disord, 2021. 50: p. 102816.
2.
Solaro, C., et al., The changing face of multiple sclerosis: Prevalence and incidence in an aging population. Mult Scler, 2015. 21(10): p. 1244-50.
3.
Barnett, M.H., et al., Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci, 2003. 213(1-2): p. 1-6.
4.
Lotti, C.B.C., et al., Late onset multiple sclerosis: concerns in aging patients. Arq Neuropsiquiatr, 2017. 75(7): p. 451-456.
5.
Buscarinu, M.C., et al., Late-Onset MS: Disease Course and Safety-Efficacy of DMTS. Frontiers in Neurology, 2022. 13.
6.
Musella, A., et al., Interplay Between Age and Neuroinflammation in Multiple Sclerosis: Effects on Motor and Cognitive Functions. Frontiers in Aging Neuroscience, 2018. 10.
7.
Nasiri, E., et al., Radiological features of late-onset multiple sclerosis: A systematic review and meta-analysis. Journal of Neuroradiology, 2023. 50(6): p. 571-580.
8.
Kapoor, R., et al., Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol, 2018. 17(5): p. 405-415.
9.
Montalban, X., et al., Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. New England Journal of Medicine, 2016. 376(3): p. 209-220.
10.
Giovannoni, G., et al., A Placebo-Controlled Trial of Oral Cladribine for Relapsing Multiple Sclerosis. New England Journal of Medicine, 2010. 362(5): p. 416-426.
11.
Filippini, G., et al., Rituximab for people with multiple sclerosis. Cochrane Database Syst Rev. 2021 Feb 16;2021(2):CD013874. doi: 10.1002/14651858.CD013874. eCollection 2021.

Authors

  • Huynh Thi Nhu Y
  • Nguyen Xuan Dieu
  • Nguyen Ngoc Luong
  • Hoang Tien Trong Nghia

Files

Article Views3
Document Views4
Downloads2
Section Articles
Category Ca lâm sàng